Latest news with #CarisLifeSciences
Bloomberg
6 hours ago
- Business
- Bloomberg
Medtech Caris Life Sciences Seeks to Raise $423.5 Million in IPO
Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, is seeking to raise $423.5 million in an initial public offering. The Sixth Street Partners -backed company plans to market 23.5 million shares for $16 to $18 each, according to its filing on Monday with the US Securities and Exchange Commission. Neuberger Berman indicated it would be interested in buying as much as $75 million of the offering at the IPO price, the filing shows.
Yahoo
7 hours ago
- Business
- Yahoo
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
(Reuters) -Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.35 billion in its initial public offering in the United States. Irving, Texas-based Caris plans to raise up to $424 million by offering 23.5 million shares priced between $16 and $18 apiece. The IPO market is heating up as high-profile companies move ahead with their stock market listings in a calmer period after tariff-related volatility stifled deal activity earlier this year. In 2021, Caris raised $830 million at a $7.83 billion valuation in a funding round led by investment firm Sixth Street. Caris will trade on the Nasdaq under the symbol "CAI." BofA Securities, J.P. Morgan, Goldman Sachs, and Citigroup are the lead underwriters for the offering.
Reuters
7 hours ago
- Business
- Reuters
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
June 9 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.35 billion in its initial public offering in the United States. Irving, Texas-based Caris plans to raise up to $424 million by offering 23.5 million shares priced between $16 and $18 apiece. The IPO market is heating up as high-profile companies move ahead with their stock market listings in a calmer period after tariff-related volatility stifled deal activity earlier this year. In 2021, Caris raised $830 million at a $7.83 billion valuation in a funding round led by investment firm Sixth Street. Caris will trade on the Nasdaq under the symbol "CAI." BofA Securities, J.P. Morgan, Goldman Sachs, and Citigroup are the lead underwriters for the offering.
Business Journals
30-05-2025
- Business
- Business Journals
Caris Life Sciences files for IPO
Irving-based Caris Life Sciences filed to go public on the Nasdaq and revealed a significant revenue jump between 2023 and 2024. Still, the company remains unprofitable and is grappling with a large amoutn of debt. Learn all about what could be North Texas' next public company in this story, and check out a list of the region's biggest Wall Street movers and shakers.
Bloomberg
23-05-2025
- Business
- Bloomberg
Sixth Street Partners-Backed Caris Life Sciences Files for IPO
Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, filed for an initial public offering, disclosing shrinking losses and growing revenue. The Sixth Street Partners -backed company had a net loss of $127 million on revenue of $120.9 million for the first three months of 2025, compared with a net loss of $134.1 million on revenue of $80.7 million in the same period a year earlier, according to its filing Friday with the US Securities and Exchange Commission.
